Fig. 9.

Gene expression for (A) dopamine- and cyclic adenosine monophosphate-regulated phosphoprotein, Mr 32 kDA (DARPP-32), (C) peroxisome proliferator-activated receptor (PPAR)γ, and (D) tumour necrosis factor (TNF)-α, and (B) DARPP-32 immunostaining measured in the striatum of R6/2 mice (10 weeks after birth) treated from the age of 4 weeks with cannabigerol (CBG) or vehicle (Tween 80-saline). Values correspond to fold of change (gene expression) or percentage (immunostaining) over wild-type animals and are expressed as means ± SEM for 6–8 animals per group. Data were subjected to one-way analysis of variance followed by the Student–Newman–Keuls test (*P < 0.05, **P < 0.01, ***P < 0.005 compared with wild-type animals treated with vehicle)